John Norris's deep experience in business, academia and the federal government brings great benefits to CereMedix as we advance our development of unique life-saving therapeutics to address unmet needs in ischemic reperfusion
By activating innate mechanisms of metabolic protection in the body, RIC has been shown to reduce the larger damage from ischemic reperfusion
injury to cardiac and other organs, including myocardial infarctions, cardiac surgery, stroke, trauma, and organ transplantation.
Additionally, the naturally occurring lead drug is used as a scaffold to developing a new class of therapeutics, which focuses on cardioprotection against ischemic reperfusion
injury and stroke.
is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine including the prevention and treatment of ischemia, ischemic reperfusion
injury, and stroke.
Together, Biotecnol and Digna Biotech are developing recombinant human CT-1 as a first-in-class drug to reduce ischemic reperfusion
injury associated with organ transplantation and liver resection due to primary and secondary tumors, mainly originating from colorectal cancers.
Table 1 Effects of silymarin and silibinin on cerebral infarction in cerebral ischemic reperfusion
(CI/R) injured rats.
Ischemia and ischemic reperfusion
injury remain a major inadequately treated area of cardiovascular medicine.
The Phase II trial was an investigation of the cardioprotective effects of MC-1 in mitigating damage caused by ischemia and ischemic reperfusion
in heart disease patients undergoing angioplasty.
ischemic stroke) and to prevent injury from ischemic reperfusion
The Company announced that MC-1 received FDA Fast Track designation as a treatment to reduce cardiovascular and cerebrovascular events associated with ischemic and/or ischemic reperfusion
injury in patients experiencing percutaneous coronary interventions, coronary artery bypass graft surgery and acute coronary syndrome.
The promising clinical results seen with MC-1, first in the angioplasty setting of the MEND-1 study and now in the setting of bypass surgery, suggest that MC-1 could represent a major therapeutic breakthrough in the treatment of acute ischemia and ischemic reperfusion
The article titled "MC-1: Novel Therapeutic Applications to Reduce Ischemic Injury", provides new in vivo and in vitro analysis of MC-1's efficacy in reducing ischemic reperfusion
injury, in addition to previously published clinical data.